Back to search
FDAFDA · Food and drugs·Recall number D-0913-2023

Sunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0093-8199-28

Published July 19, 2023 · Recall initiated: July 5, 2023

Summary

FDA records drug Class II recall D-0913-2023, published July 19, 2023 and initiated July 5, 2023. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 180 bottles; Lot: Lot # 100037220, Exp 10/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Moisture Limits: Water (moisture) content above the approved product specifications.

What to do

Voluntary: Firm initiated · Letter

Get an email if SUNITINIB MALATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
SUNITINIB MALATE
Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
Product was distributed to 3 wholesalers/distributors who further distributed the product Nationwide in the USA.
Lot
Lot # 100037220, Exp 10/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0093-8199-28 recalled?

Yes. FDA published recall D-0913-2023 on July 19, 2023. Reported hazard: Failed Moisture Limits: Water (moisture) content above the approved product specifications.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: SUNITINIB MALATE.